This study aimed to investigate the efficacy of gene therapy for treating autoimmune sensorineural hearing loss (ASHL) via local\nadministration of a recombinant adenovirus vector containing the Fas ligand or interleukin IL-10 gene. Guinea pigs were divided\ninto four groups, with different microinjections in the scala tympani. Group A were injected with FasL-EGFP, B with IL-10-EGFP,\nC with EGFP, and D with artificial perilymph. Seven days later, auditory brain-stem response (ABR) was tested, and the temporal\nbone was stained and observed by light microscopy.The spiral ligament and basementmembranewere observed using transmission\nelectron microscopy. FasL and IL-10 expression were examined using immunofluorescence histochemistry. Immunohistochemical\nanalysis showed that the recombinant adenovirus vector in Groups A, B, and C can transfect the stria vascularis, the spiral ligament,\nthe organ of Corti, the spiral ganglion, the region surrounding the small blood vessel in the modiolus, and the cochlear bone\nwall. Compared with those in Groups C and D, the ABR wave III mean thresholds were significantly lower and the inner ear\nimmunoinflammatory responses in Groups A and B were significantly alleviated. Inhibition of immunoinflammatory response\nalleviated immunoinflammatory injury and auditory dysfunction. This technique shows potential as a novel therapy for ASHL.
Loading....